866-997-4948(US-Canada Toll Free)

Huntington Disease - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 299 Pages

Huntington Disease - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Huntington Disease - Pipeline Review, H1 2017, provides an overview of the Huntington Disease (Central Nervous System) pipeline landscape.

Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Huntington Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 6, 50 and 18 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 22 and 5 molecules, respectively.

Huntington Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Huntington Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Huntington Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Huntington Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Huntington Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Huntington Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 6
Huntington Disease - Overview 7
Huntington Disease - Therapeutics Development 8
Huntington Disease - Therapeutics Assessment 24
Huntington Disease - Companies Involved in Therapeutics Development 36
Huntington Disease - Drug Profiles 64
Huntington Disease - Dormant Projects 270
Huntington Disease - Discontinued Products 275
Huntington Disease - Product Development Milestones 276
Appendix 287

List of Tables
Number of Products under Development for Huntington Disease, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Huntington Disease - Pipeline by Addex Therapeutics Ltd, H1 2017
Huntington Disease - Pipeline by AFFiRiS AG, H1 2017
Huntington Disease - Pipeline by Angita BV, H1 2017
Huntington Disease - Pipeline by Annexon Inc, H1 2017
Huntington Disease - Pipeline by Azevan Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by BioCrea GmbH, H1 2017
Huntington Disease - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by Celon Pharma SA, H1 2017
Huntington Disease - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
Huntington Disease - Pipeline by Evotec AG, H1 2017
Huntington Disease - Pipeline by Galenea Corp, H1 2017
Huntington Disease - Pipeline by Genervon Biopharmaceuticals LLC, H1 2017
Huntington Disease - Pipeline by Horizon Pharma Plc, H1 2017
Huntington Disease - Pipeline by Immungenetics AG, H1 2017
Huntington Disease - Pipeline by InMed Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by Ipsen SA, H1 2017
Huntington Disease - Pipeline by Kadmon Corp LLC, H1 2017
Huntington Disease - Pipeline by KineMed Inc, H1 2017
Huntington Disease - Pipeline by Krenitsky Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by Living Cell Technologies Ltd, H1 2017
Huntington Disease - Pipeline by Medesis Pharma SA, H1 2017
Huntington Disease - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by Neuralstem Inc, H1 2017
Huntington Disease - Pipeline by Neurimmune Holding AG, H1 2017
Huntington Disease - Pipeline by Neurocrine Biosciences Inc, H1 2017
Huntington Disease - Pipeline by NeuroNascent Inc, H1 2017
Huntington Disease - Pipeline by New World Laboratories Inc, H1 2017
Huntington Disease - Pipeline by nLife Therapeutics SL, H1 2017
Huntington Disease - Pipeline by Novartis AG, H1 2017
Huntington Disease - Pipeline by NsGene A/S, H1 2017
Huntington Disease - Pipeline by Omeros Corp, H1 2017
Huntington Disease - Pipeline by Oryzon Genomics SA, H1 2017
Huntington Disease - Pipeline by Probiodrug AG, H1 2017
Huntington Disease - Pipeline by ProQR Therapeutics NV, H1 2017
Huntington Disease - Pipeline by PTC Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by QR Pharma Inc, H1 2017
Huntington Disease - Pipeline by reMYND NV, H1 2017
Huntington Disease - Pipeline by Sage Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by Shire Plc, H1 2017
Huntington Disease - Pipeline by SOM Biotech SL, H1 2017
Huntington Disease - Pipeline by Spark Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by Stealth BioTherapeutics Inc, H1 2017
Huntington Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Huntington Disease - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
Huntington Disease - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2017
Huntington Disease - Pipeline by UniQure NV, H1 2017
Huntington Disease - Pipeline by Vaccinex Inc, H1 2017
Huntington Disease - Pipeline by Vertex Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by VistaGen Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by Vitality Biopharma Inc, H1 2017
Huntington Disease - Pipeline by VivaCell Biotechnology Espana SL, H1 2017
Huntington Disease - Pipeline by Voyager Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by Vybion Inc, H1 2017
Huntington Disease - Pipeline by WAVE Life Sciences Ltd, H1 2017
Huntington Disease - Pipeline by Wellstat Therapeutics Corp, H1 2017
Huntington Disease - Dormant Projects, H1 2017
Huntington Disease - Dormant Projects, H1 2017 (Contd..1), H1 2017
Huntington Disease - Dormant Projects, H1 2017 (Contd..2), H1 2017
Huntington Disease - Dormant Projects, H1 2017 (Contd..3), H1 2017
Huntington Disease - Dormant Projects, H1 2017 (Contd..4), H1 2017
Huntington Disease - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Huntington Disease, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *